Unknown

Dataset Information

0

Efficacy and safety of prolonged-release tacrolimus in stable pediatric allograft recipients converted from immediate-release tacrolimus - a Phase 2, open-label, single-arm, one-way crossover study.


ABSTRACT: There are limited clinical data regarding prolonged-release tacrolimus (PR-T) use in pediatric transplant recipients. This Phase 2 study assessed the efficacy and safety of PR-T in stable pediatric kidney, liver, and heart transplant recipients (aged ?5 to ?16 years) over 1 year following conversion from immediate-release tacrolimus (IR-T), on a 1:1 mg total-daily-dose basis. Endpoints included the incidence of acute rejection (AR), a composite endpoint of efficacy failure (death, graft loss, biopsy-confirmed AR, and unknown outcome), and safety. Tacrolimus dose and whole-blood trough levels (target 3.5-15 ng/ml) were also evaluated. Overall, 79 patients (kidney, n = 48; liver, n = 29; heart, n = 2) were assessed. Following conversion, tacrolimus dose and trough levels remained stable; however, 7.6-17.7% of patients across follow-up visits had trough levels below the target range. Two (2.5%) patients had AR, and 3 (3.8%) had efficacy failure. No graft loss or deaths were reported. No new safety signals were identified. Drug-related treatment-emergent adverse events occurred in 28 patients (35.4%); most were mild, and all resolved. This study suggests that IR-T to PR-T conversion is effective and well tolerated over 1 year in pediatric transplant recipients and highlights the importance of therapeutic drug monitoring to maintain target tacrolimus trough levels.

SUBMITTER: Rubik J 

PROVIDER: S-EPMC6852421 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy and safety of prolonged-release tacrolimus in stable pediatric allograft recipients converted from immediate-release tacrolimus - a Phase 2, open-label, single-arm, one-way crossover study.

Rubik Jacek J   Debray Dominique D   Kelly Deirdre D   Iserin Franck F   Webb Nicholas J A NJA   Czubkowski Piotr P   Vondrak Karel K   Sellier-Leclerc Anne-Laure AL   Rivet Christine C   Riva Silvia S   Tönshoff Burkhard B   D'Antiga Lorenzo L   Marks Stephen D SD   Reding Raymond R   Kazeem Gbenga G   Undre Nasrullah N  

Transplant international : official journal of the European Society for Organ Transplantation 20190827 11


There are limited clinical data regarding prolonged-release tacrolimus (PR-T) use in pediatric transplant recipients. This Phase 2 study assessed the efficacy and safety of PR-T in stable pediatric kidney, liver, and heart transplant recipients (aged ≥5 to ≤16 years) over 1 year following conversion from immediate-release tacrolimus (IR-T), on a 1:1 mg total-daily-dose basis. Endpoints included the incidence of acute rejection (AR), a composite endpoint of efficacy failure (death, graft loss, bi  ...[more]

Similar Datasets

| S-EPMC6900073 | biostudies-literature
| S-EPMC6624387 | biostudies-literature
| S-EPMC6752107 | biostudies-literature
| S-EPMC6728630 | biostudies-literature
| S-EPMC5024030 | biostudies-literature
| S-EPMC7412936 | biostudies-literature
| S-EPMC10222168 | biostudies-literature
| S-EPMC8056872 | biostudies-literature
| S-EPMC6824349 | biostudies-literature
| S-EPMC6248274 | biostudies-literature